Joint Health
XBiotech's Vilamakitug Enters Phase II Trial for Axial SpA
The IND application completed its 30-day FDA review without a clinical hold, opening U.S. patient enrollment for the an…
The IND application completed its 30-day FDA review without a clinical hold, opening U.S. patient enrollment for the an…